Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
| Autor: | Heerspink, H. J.L., Stefansson, B., Chertow, G., Correa-Rotter, R., Greene, Tom, Hou, Fan Fan, Lindberg, Magnus, McMurray, John, Rossing, P., Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C., Wheeler, D. C., Greene, T., Hou, F. F., McMurray, J., Toto, R., Langkilde, A. M., Pfeffer, Marc A., Pocock, Stuart, Swedberg, Karl, Rouleau, Jean L., Chaturvedi, Nishi, Ivanovich, Peter, Levey, Andrew S., Christ-Schmidt, Heidi, Mann, Johannes, Held, Claes, Varenhorst, Christoph, Holmgren, Pernilla, Hallberg, Theresa, Douthat, Walter, Filho, Roberto Pecoits, Cherney, David, Persson, Frederik, Haller, Hermann, Wittmann, István, Khullar, Dinesh, Naoki, Kashihara, Correa-Rotter, Richardo, Escudero, Elizabeth, Isidto, Rey, Nowicki, Michal, Batiushin, Mikhail |
|---|---|
| Přispěvatelé: | Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET) |
| Rok vydání: | 2020 |
| Předmět: |
Male
Type 2 diabetes 030204 cardiovascular system & hematology urologic and male genital diseases sodium-glucose co-transporter inhibitor law.invention chemistry.chemical_compound 0302 clinical medicine Glucosides Randomized controlled trial law Chronic kidney disease Randomized controlled clinical trial Clinical endpoint Diabetic Nephropathies 030212 general & internal medicine Dapagliflozin randomized controlled clinical trial Aged 80 and over sodium–glucose co-transporter inhibitor Middle Aged Prognosis Cardiovascular Diseases Research Design Nephrology Female Glomerular Filtration Rate Adult medicine.medical_specialty Adolescent Renal function Young Adult 03 medical and health sciences Double-Blind Method Clinical Research Diabetes mellitus Internal medicine medicine Humans Benzhydryl Compounds Renal Insufficiency Chronic Sodium-Glucose Transporter 2 Inhibitors Aged Transplantation Creatinine business.industry dapagliflozin medicine.disease Sodiumglucose co-transporter inhibitor Diabetes Mellitus Type 2 chemistry ORIGINAL ARTICLES INHIBITORS business chronic kidney disease Kidney disease |
| Zdroj: | Nephrology Dialysis Transplantation Nephrology Dialysis Transplantation, 35(2), 274-282. Oxford University Press Heerspink, H J L, Stefansson, B, Chertow, G, Correa-Rotter, R, Greene, T, Hou, F F, Lindberg, M, McMurray, J, Rossing, P, Toto, R, Langkilde, A M, Wheeler, D C, Heerspink, H J L, Wheeler, D C, Chertow, G, Correa-Rotter, R, Greene, T, Hou, F F, McMurray, J, Rossing, P, Toto, R, Stefansson, B, Langkilde, A M, Pfeffer, M A, Pocock, S, Swedberg, K, Rouleau, J L, Chaturvedi, N, Ivanovich, P, Levey, A S, Christ-Schmidt, H, Mann, J, Held, C, Varenhorst, C, Holmgren, P, Hallberg, T, Douthat, W, Filho, R P, Cherney, D, Hou, F F, Persson, F, Haller, H, Wittmann, I, Khullar, D, Naoki, K, Correa-Rotter, R, Escudero, E, Isidto, R, Nowicki, M, Batiushin, M & DAPA-CKD Investigators 2020, ' Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial ', Nephrology Dialysis Transplantation, vol. 35, no. 2, pp. 274-282 . https://doi.org/10.1093/ndt/gfz290 |
| ISSN: | 1460-2385 0931-0509 |
| Popis: | Background Recent cardiovascular outcome trials have shown that sodium–glucose co-transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high cardiovascular risk. Whether these benefits extend to CKD patients without type 2 diabetes or cardiovascular disease is unknown. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial (NCT03036150) will assess the effect of the SGLT2 inhibitor dapagliflozin on renal and cardiovascular events in a broad range of patients with CKD with and without diabetes. Methods DAPA-CKD is a randomized, double-blind, placebo-controlled, trial in which ∼4300 patients with CKD Stages 2–4 and elevated urinary albumin excretion will be enrolled. The vast majority will be receiving a maximum tolerated dose of a renin–angiotensin system inhibitor at enrolment. Results After a screening assessment, eligible patients with a urinary albumin:creatinine ratio ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 are randomly assigned to placebo or dapagliflozin 10 mg/day. Enrolment is monitored to ensure that at least 30% of patients do not have diabetes and that no more than 10% have an eGFR >60 mL/min/1.73 m2. The primary endpoint is a composite of a sustained decline in eGFR of ≥50%, end-stage renal disease, renal death or cardiovascular death. The trial will conclude when 681 primary renal events have occurred, providing 90% power to detect a 22% relative risk reduction (α level of 0.05). Conclusion DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes. Graphical Abstract Graphical Abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|